Using the latest TTM figures, Jazz Pharmaceuticals shows a gross margin of 88.4%, an operating margin of 19.5%, an EBITDA margin of 35.1%, and a net margin of 20.4%. Margin expansion was strongest in net margin, which increased by 30.3 percentage points. Gross margin had the strongest contraction, declining by 0.3 percentage points.
Over the last 3 years, Jazz Pharmaceuticals recorded average margins of 88.77% gross, 7.35% operating, 23.65% EBITDA, and 5.53% net. Jazz Pharmaceuticals's current performance shows that operating, EBITDA, and net margins are above their three-year averages and gross margin is below its three-year average.
Jazz Pharmaceuticals's operating margin expanded by 26.6 percentage points, EBITDA margin by 26 percentage points, and net margin by 30.3 percentage points, but gross margin contracted by 0.3 percentage points.
Across the last 3 years, Jazz Pharmaceuticals's gross margin stood at 88.77%. Compared with its three-year average, Jazz Pharmaceuticals's current gross margin is 88.4% and is 0.4 percentage points below its three-year average. Gross margin was highest at 89.5% in Mar 2024 and lowest at 88% in Mar 2026.
Across the last 3 years, Jazz Pharmaceuticals's operating margin averaged 7.35%. As of the latest period, Jazz Pharmaceuticals's current operating margin is 19.5%, which is 12.2 percentage points above its three-year average. Operating margin was highest at 19.5% in Jun 2026 and lowest at -11.9% in Sep 2025.
Over the last 3 years, Jazz Pharmaceuticals's EBITDA margin averaged 23.65%. The current EBITDA margin of 35.1% is 11.5 percentage points above its three-year average. During this period, EBITDA margin reached a high of 35.1% in Jun 2026 and a low of 4.4% in Sep 2025.
Jazz Pharmaceuticals recorded an average net margin of 5.53% across the last 3 years. Jazz Pharmaceuticals's current net margin is 20.4% and is 14.9 percentage points above its three-year average. Net margin was highest at 20.4% in Jun 2026 and lowest at -9.9% in Jun 2025.
Jazz Pharmaceuticals's gross margin of 88.4% is above the Healthcare sector and the industry average. Compared to its Healthcare sector average of 68.3%, Jazz Pharmaceuticals's gross margin is 29% higher.
The current gross margin for JAZZ is 88.4% as of Jun 30, 2026.
The current operating margin for JAZZ is 19.5% as of Jun 30, 2026.
As of Jun 30, 2026, JAZZ has an EBITDA margin of 35.1%.
For the period ending Jun 30, 2026, JAZZ recorded a net margin of 20.4%.
Jazz Pharmaceuticals's gross, operating, EBITDA, and net margins averaged 88.8% gross, 7.4% operating, 23.7% EBITDA, and 5.5% net over the last 3 years.
Across the 5-year period, JAZZ posted its highest margins at 89.5% gross in Mar 2024, 19.5% operating in Jun 2026, 35.1% EBITDA in Jun 2026, and 20.4% net in Jun 2026.
In the last 5 years, the lowest margins reported by JAZZ were 84.4% gross in Mar 2022, -11.9% operating in Sep 2025, 4.4% EBITDA in Sep 2025, and -13.6% net in Mar 2022.